Lipum is taking a new approach to treating chronic inflammatory diseases by targeting the protein BSSL. Through a collaboration with the Karolinska Institute, the company aims to gain deeper insights into BSSL’s role in inflammation and clarify the mechanism of action of their lead drug candidate, SOL-116. BioStock spoke with project leader Associate Professor Bence Réthi to learn more.
Read the full article at biostock.se:
https://www.biostock.se/en/2024/10/lipum-and-ki-explore-the-mode-of-action/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se
